Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.68 |
| ▸ | MAPT | P10636 | 7/20 | 0.68 |
| ▸ | NPC1 | O15118 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12975239 | 0.90 | RAB9A (0.60) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL22130591 | 0.88 | RAB9A (0.54) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL13144514 | 0.85 | MAPT (0.70) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL163667 | 0.84 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL9454202 | 0.84 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL19208916 | 0.84 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL285573 | 0.84 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL1438508 | 0.84 | RAB9A (0.66) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL12548708 | 0.83 | RAB9A (0.60) | RAB9AMAPTNPC1ALDH1A1MEN1 | |
| SCHEMBL3001536 | 0.82 | RAB9A (0.64) | RAB9AMAPTNPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4709723-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | disclosed |
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2025-01-02 | — | — | US | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| WO-1998017648-A1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LIMITED (GB) | 1998-04-30 | — | — | WO | disclosed |
| EP-0807633-A2 | Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones | PFIZER INC. (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0778821-A1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LIMITED (GB) | 1997-06-18 | — | — | EP | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
| WO-1996006822-A1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LIMITED (GB) | 1996-03-07 | — | — | WO | disclosed |
| EP-0154132-B1 | 6-ALKYLIDENE PENEMS, THEIR PREPARATION AND USE, AND INTERMEDIATES | BEECHAM GROUP PLC (GB) | 1992-01-08 | — | — | EP | disclosed |
| US-4798828-A | LACTAMASE INHIBITORS | BEECHAM GROUP P.L.C. (GB) | 1989-01-17 | — | — | US | disclosed |
| EP-0154132-A1 | 6-Alkylidene penems, their preparation and use, and intermediates | BEECHAM GROUP PLC (GB) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SUCNR1, SRD5A1, GLS | RAB9A 3756/4885MAPT 1594/4885NPC1 2369/4885 |
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | LPAR1, LPAR2, LPAR4 | RAB9A 1177/4885MAPT 4780/4885NPC1 520/4885 |
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | RAB9A 999/4885MAPT 581/4885NPC1 304/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | RAB9A 1384/4885MAPT 2157/4885NPC1 224/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | RAB9A 384/4885MAPT 2865/4885NPC1 399/4885 |
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | RAB9A 2726/4885MAPT 1032/4885NPC1 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.